ArticleCardiology research and practice2011
Peripheral vascular dysfunction in chronic kidney disease.
Article in Cardiology research and practice, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 75 citations in OpenAlex.
- Cutaneous Microvascular Functional Reserve is Associated with Kidney Function and Histopathologic Injury in CKD: The MAP-CKD Study.medRxiv : the preprint server for health sciences · 2026Article
- Intersecting Pathways of Inflammation, Oxidative Stress, and Atherogenesis in the Evaluation of CKD: Emerging Biomarkers PCSK9, EPHX2, AOPPs, and TBARSs.Life (Basel, Switzerland) · 2025Review
- Pathophysiology of Wound Development and Chronicity in Renal Disease: A Narrative Review.International wound journal · 2025Review
- Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI.BMC nephrology · 2025Article
- Bone Marrow Findings in Patients With Renal Disease: Experience of a Single Tertiary Care Center in Bihar.Cureus · 2025Article
- Curcumin Supplementation and Vascular and Cognitive Function in Chronic Kidney Disease: A Randomized Controlled Trial.Antioxidants (Basel, Switzerland) · 2024Article
- Differences in peripheral microcirculatory blood flow regulation in chronic kidney disease based on wavelet analysis of resting near-infrared spectroscopy.Microvascular research · 2024Article
- Deletion of the aryl hydrocarbon receptor in endothelial cells improves ischemic angiogenesis in chronic kidney disease.American journal of physiology. Heart and circulatory physiology · 2024Article
- Building a Scaffold for Arteriovenous Fistula Maturation: Unravelling the Role of the Extracellular Matrix.International journal of molecular sciences · 2023Review
- Calciprotein Particles Induce Endothelial Dysfunction by Impairing Endothelial Nitric Oxide Metabolism.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
- Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.British journal of pharmacology · 2022Article
- Influence of Polyunsaturated Fatty Acid Intake on Kidney Functions of Rats with Chronic Renal Failure.Marine drugs · 2021Article
- Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Indoxyl sulfate impairs angiogenesis via chronic aryl hydrocarbon receptor activation.American journal of physiology. Cell physiology · 2021Article
- Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide.Journal of cellular and molecular medicine · 2020Article
- The Second Life of Methylarginines as Cardiovascular Targets.International journal of molecular sciences · 2019Review
- Altered vascular function in chronic kidney disease: evidence from passive leg movement.Physiological reports · 2019Article
- Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases.Frontiers in pharmacology · 2019Review
- Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM.European journal of immunology · 2018Article
- Dietary intake of inorganic phosphorus has a stronger influence on vascular-endothelium function than organic phosphorus.Journal of clinical biochemistry and nutrition · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There is an increased prevalence of cardiovascular disease- (CVD-) related mortality in patients with chronic kidney disease (CKD). Endothelial dysfunction is a primary event in the development of atherosclerosis and hypertension and likely contributes to the elevated cardiovascular risk in CKD. Endothelial dysfunction has been shown to occur in the peripheral vasculature of patients with both severe and moderate CKD. Mechanisms include oxidative stress, L-arginine deficiency, and elevated plasma levels of ADMA. Interventions designed to restore vascular function in patients with CKD have shown mixed results. Evidence from cell culture studies suggest that the accumulation of uremic toxins inhibits L-arginine transport and reduces nitric oxide production. The results of these studies suggest that endothelial dysfunction may become less reversible with advancing kidney disease. The purpose of this paper is to present the current literature pertaining to potential mechanisms of peripheral vascular dysfunction in chronic kidney disease and to identify possible targets for treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.